Please enable JavaScript.
Coggle requires JavaScript to display documents.
ERECTILE DYSFUNCTION + osteoporosis, osteoporosis, ERECTILE DYSFUNCTION,…
-
osteoporosis
Denosumab
-
first-line agent for osteoporosis,
SERMs
-
Raloxifene
-
without increasing the risk of endometrial cancer, and it decreases the risk ofinvasive breast cancer
-
-
-
Bisphosphonates
alendronate, risedronate, and zoledronic acid جماعة الدرون
-
-
-
-
Calcitonin
but it is less effective than other agents,
-
ERECTILE DYSFUNCTION
PDE-5 inhibitors
sildenafil, vardenafil, tadalafil, and avanafil,
-
"Inhibit PDE-5, the isozyme responsible for degradation of cGMP which mediate the smooth muscle relaxation in the corpus cavernosum."
-
Adverse effects:
Headache, flushing, dyspepsia, and nasal congestion are the most frequent side effects
rare
-
Sudden hearing loss has also been reported. •Tadalafil has been associated with back pain and myalgias. • Cardiovascular complications.
• Priapism (a painful, prolonged erection).
-
-
Adverse effects
Musculoskeletal pain. • Alendronate, risedronate, and ibandronate associated with esophagitis and esophageal ulcers. To minimize esophageal irritation, patients should remain upright after taking oral bisphosphonates."
increase the risk of endometrial cancer (when used without a progestin in women with an intact uterus), breast cancer, stroke, venous thromboembolism, and coronary events, it is no longer recommended as a preventive
therapy for osteoporosis
-
-
-
-
-
raloxifene should be used as an alternative to bisphosphonates or denosumabin the treatment of
postmenopausal osteoporosis
-